102
Participants
Start Date
May 8, 2013
Primary Completion Date
September 12, 2019
Study Completion Date
October 24, 2024
Cabozantinib S-malate
Given PO
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
UPMC-Magee Womens Hospital, Pittsburgh
Fox Chase Cancer Center, Philadelphia
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
University of Michigan Comprehensive Cancer Center, Ann Arbor
NorthShore University HealthSystem-Evanston Hospital, Evanston
University of Chicago Comprehensive Cancer Center, Chicago
Decatur Memorial Hospital, Decatur
Southern Illinois University School of Medicine, Springfield
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
City of Hope South Pasadena, South Pasadena
Arthur J E Child Comprehensive Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Kingston Health Sciences Centre, Kingston
London Regional Cancer Program, London
Ottawa Hospital and Cancer Center-General Campus, Ottawa
University Health Network-Princess Margaret Hospital, Toronto
National Cancer Institute (NCI)
NIH